The EEF1D Knockout HAP1 Polyclonal Cells product consists of a human HAP1 cell population edited by CRISPR/Cas9 to disrupt the EEF1D gene. This polyclonal knockout pool incorporates diverse gene-disruption events, avoiding artifacts of single clonal selection and enabling robust loss-of-function analysis.
HAP1 is a near-haploid cell line originally derived from KBM-7 chronic myeloid leukemia (CML) cells. Its unique karyotype??predominantly haploid except for a disomic region of chromosome 15??simplifies knockout studies by requiring disruption of only a single allele to achieve functional nullity. The CML origin renders HAP1 cells inherently relevant for studying cancer-associated signaling, metabolic reprogramming, and drug resistance mechanisms.
EEF1D encodes the delta subunit of the eukaryotic elongation factor 1 (eEF1) complex, which in its full form comprises EEF1A, EEF1B2, EEF1D, and EEF1G. The EEF1D subunit serves as the guanine nucleotide exchange factor (GEF) for EEF1A, facilitating GDP-to-GTP exchange and enabling EEF1A to deliver aminoacyl-tRNAs to the ribosomal A-site during translation elongation. This process is tightly controlled by mTOR signaling, which responds to growth factors and nutrient availability. EEF1D directly interacts with the other eEF1 subunits and with valyl-tRNA synthetase. Disruption of EEF1D therefore attenuates elongation, leading to reduced global protein synthesis and impaired cell proliferation. Additionally, eEF1 complex members have been implicated in MAPK/ERK pathway modulation, connecting EEF1D to broader oncogenic signaling networks.
In the HAP1 leukemic context, EEF1D knockout permits dissection of the unique translational dependencies of CML cells. The near-haploid background may uncover synthetic lethal relationships with other translation factors or upstream kinases, providing insights into therapeutic vulnerabilities. For example, loss of EEF1D could sensitize cells to mTOR inhibitors or to drugs targeting other components of the eEF1 complex. This model also allows exploration of how viral pathogens, such as coronaviruses or flaviviruses, co-opt host translational machinery for replication.
Key applications include ribosome profiling to assess global translation elongation rates, puromycin incorporation assays to quantify nascent protein synthesis, and western blotting or RT-qPCR to confirm knockdown and downstream effects. Proliferation and viability assays can evaluate the functional consequences of EEF1D loss, while the polyclonal cell pool is particularly well suited for pooled CRISPR screens and host factor dependency studies for viral replication. For additional product information, licensing details, or technical inquiries, please contact Ascent Research.
